title: Obesity-related known and candidate SNP markers can significantly change affinity of TATA-binding protein for human gene promoters.
abstract: BACKGROUND
  Obesity affects quality of life and life expectancy and is associated with cardiovascular disorders, cancer, diabetes, reproductive disorders in women, prostate diseases in men, and congenital anomalies in children. The use of single nucleotide polymorphism (SNP) markers of diseases and drug responses (i.e., significant differences of personal genomes of patients from the reference human genome) can help physicians to improve treatment. Clinical research can validate SNP markers via genotyping of patients and demonstration that SNP alleles are significantly more frequent in patients than in healthy people. The search for biomedical SNP markers of interest can be accelerated by computer-based analysis of hundreds of millions of SNPs in the 1000 Genomes project because of selection of the most meaningful candidate SNP markers and elimination of neutral SNPs.
  
  
  RESULTS
  We cross-validated the output of two computer-based methods: DNA sequence analysis using Web service SNP_TATA_Comparator and keyword search for articles on comorbidities of obesity. Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity). Using an electrophoretic mobility shift assay under nonequilibrium conditions, we empirically validated the statistical significance (α < 0.00025) of the differences in TBP affinity values between the minor and ancestral alleles of 4 out of the 22 SNPs: rs200487063, rs201381696, rs34104384, and rs183433761. We also measured half-life (t1/2), Gibbs free energy change (ΔG), and the association and dissociation rate constants, ka and kd, of the TBP-DNA complex for these SNPs.
  
  
  CONCLUSIONS
  Validation of the 22 candidate SNP markers by proper clinical protocols appears to have a strong rationale and may advance postgenomic predictive preventive personalized medicine.
authors.forename: Olga V
authors.initials: OV
authors.lastname: Arkova
authors.forename: Mikhail P
authors.initials: MP
authors.lastname: Ponomarenko
authors.forename: Dmitry A
authors.initials: DA
authors.lastname: Rasskazov
authors.forename: Irina A
authors.initials: IA
authors.lastname: Drachkova
authors.forename: Tatjana V
authors.initials: TV
authors.lastname: Arshinova
authors.forename: Petr M
authors.initials: PM
authors.lastname: Ponomarenko
authors.forename: Ludmila K
authors.initials: LK
authors.lastname: Savinkova
authors.forename: Nikolay A
authors.initials: NA
authors.lastname: Kolchanov
mesh_terms: D005819:Genetic Markers; D006801:Humans; D009765:Obesity / Q000235:genetics* / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D035181:TATA-Box Binding Protein / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D005819:Genetic Markers; D035181:TATA-Box Binding Protein